When does low normal blood pressure become too low? The J-curve phenomenon

References

• Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, 13611m M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P. Kjeldsen SE, Laurent 5, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P. Zamorano JL, Achenbach 5, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P. Knuuti J, Kolh P. Lancellotti P. Linhart A, Nihoyannopoulos P. Piepoli MF, Ponikowski P. Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker 5, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest 5, Derumeaux GA, Erdine 5, Farsang C, Funck-Brentano C, Gerc V. Germano G, Gielen 5, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J2013; 34:2159–219.
   Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent 5, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber 5, Tendera M, Widimsky P. Zamorano JL, Erdine 5, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos 5, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine 5, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P. Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.
   Google Scholar
• Kaplan NM. The diastolic J curve: alive and threatening. Hypertension 2011; 58: 751–3.
   Google Scholar
• Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol 2009; 54: 1827–34.
   Google Scholar
• Owens P. O’Brien E. Hypotension in patients with coronary disease: can profound hypotensive events cause myocardial ischaemic events? Heart 1999; 82: 477–81.
   Google Scholar
• Merlo J, Ranstam J, Liedholm H, Hedblad B, Lindberg G, Lindblad U, Isacsson SO, Melander A, Rh’stam L Incidence of myocardial infarction in elderly men being treated with antihypertensive drugs: population based cohort study. BMJ 1996; 313:457–61.
   Google Scholar
• Chrysant SG. Current status of aggressive blood pressure control. World J Cardiol 2011; 3:65–71.
   Google Scholar
• Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979; 1:861–5.
   Google Scholar
• Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1:581–4.
   Google Scholar
• Samuelsson 0, Wilhelmsen L, Andersson OK, Pennert K, Berglund G. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Göteborg, Sweden. JAMA 1987; 258: 1768–76.
   Google Scholar
• Alderman MH, Ooi WL, Madhavan 5, Cohen H. Treatment induced blood pressure reduction and the risk of myocardial infarction. JAMA 1989; 262: 920–4.
   Google Scholar
• Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA 1991; 265: 489–95.
   Google Scholar
• D’Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction:the Framingham Study. BMJ 1991; 303:385–9.
   Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius 5, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–62.
   Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P. Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine 5, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–16.
   Google Scholar
• Lubsen J, Wagener G, Kirwan BA, de Brouwer 5, Poole-Wilson PA. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23: 641–8.
   Google Scholar
• Julius 5, Kjeldsen SE, Weber M, Brunner HR, Ekman 5, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–3.
   Google Scholar
• Sleight P. Redon J, Verdecchia P. Mancia G, Gao P. Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf 5; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27:1360–9.
   Google Scholar
• Bangalore 5, Messerli FH, Wun C, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC. J-curve revisited: an analysis of the Treating to New Targets (TNT) Trial. J Am Coll Cardiol 2009; 53: A217.
   Google Scholar
• Bangalore 5, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC; Treating to New Targets Steering Committee and Investigators. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010; 31: 2897–908.
   Google Scholar
• Bangalore 5, Qin J, Sloan 5, Murphy SA, Cannon CP; PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Thera py-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 2010; 122:2142–51.
   Google Scholar
• Dorresteijn JA, van der Graaf Y, Spiering W, Grobbee DE, Bots ML, Visseren FL; Secondary Manifestations of Arterial Disease Study Group. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension 2012; 59: 14–21.
   Google Scholar
• Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D, O’Leary DH, Bryan RN, Anderson M, Lumley T. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med 2001; 161: 1183–92.
   Google Scholar
• Glynn RI, L’Italien GJ, Sesso HD, Jackson EA, Buring JE. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 2002; 39:105–10.
   Google Scholar
• Mancia G, Laurent 5, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clement D, Coca A, Dominiczak A, Erdine 5, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P. Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boud-ier HA, van Zwieten PA, Viigimaa M, Zanchetti A; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121–58.
   Google Scholar
• Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
   Google Scholar
• Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058–68.
   Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703–13.
   Google Scholar
• Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 Suppl 2: B54–64.
   Google Scholar
• ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, ProbstfieldJL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575–85.
   Google Scholar
• Vamos EP, Harris M, Millett C, Pape UJ, Khunti K, Curcin V, Molokhia M, Majeed A. Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. BMJ 2012; 345: e5567.
   Google Scholar
• Haller H, Ito 5, Izzo JL Jr, Januszewicz A, Katayama 5, Menne J, Mimran A, RabelinkTJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364:907–17.
   Google Scholar
• Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304:61–8.
   Google Scholar
• Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 2011; 29:1253–69.
   Google Scholar
• Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA; 1ST Collaborative Group. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33:1315–20.
   Google Scholar
• Ovbiagele B, Diener HC, Yusuf 5, Martin RH, Cotton D, Vinisko R, Donnan GA, Bath PM; PROFESS Investigators. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 2011; 306:2137–44.
   Google Scholar
• Yusuf 5, Diener HC, Sacco RL, Cotton D, Ounpuu 5, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P. Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V. Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P. Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group.Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225–37.
   Google Scholar
• De Buyzere ML, Clement DL. Management of hypertension in peripheral arterial disease. Prog Cardiovasc Dis 2008; 50:238–63.
   Google Scholar
• Lane DA, Lip GY.Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev 2013 Dec 4; 12: CD003075. doi: 10.1002/14651858. [Epub ahead of print]
   Google Scholar
• Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003; 107: 753–6.
   Google Scholar
• Howard By, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, Howard WJ, Lee ET, Mete M, Poolaw B, Ratner RE, Russell M, Silverman A, Stylianou M, UmansJG, Wang W, Weir MR, Weissman NJ, Wilson C, Yeh F, Zhu J. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008; 299: 1678–89.
   Google Scholar
• Tobe SW, Burgess E, Lebel M. Atherosclerotic renovascular disease. Can J Cardiol 2006; 22: 623–8.
   Google Scholar
• Kalaitzidis R, Bakris GL Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens (Greenwich) 2009; 11: 345–7.
   Google Scholar
• Cornoni-Huntley J, Ostfeld AM, Taylor JO, Wallace RB, Blazer D, Berkman LF, Evans DA, Kohout FJ, Lemke JH, Scherr PA, et al. Established populations for epidemiologic studies of the elderly: study design and methodology. Aging (Milano) 1993; 5:27–37.
   Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in The Elderly Program (SHEP). JAMA 1991; 265:3255–64.
   Google Scholar
• Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887–98.
   Google Scholar
• Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, lmai Y, Kikuchi K, Ito 5, Eto T, Kimura G, Imaizumi T, Takishita 5, Ueshima H; Valsartan in Elderly Isolated Systolic Hypertension Study Group. Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension Study. Hypertension 2010; 56: 196–202.
   Google Scholar
• Protogerou AD, Safar ME, laria P. Safar H, Le Dudal K, Filipovsky J, Henry 0, Ducimetière P. Blacher J. Diastolic blood pressure and mortality in the elderly with cardiovascular disease. Hypertension 2007; 50: 172–80.
   Google Scholar
• Ivanovic BA, Tadic MV, Celic VP. To dip or not to dip? The unique relationship between different blood pressure patterns and cardiac function and structure. J Hum Hypertens 2013; 27: 62–70.
   Google Scholar